stockmarket

AstraZeneca examining impact of new COVID variant on vaccine, antibody cocktail

[ad_1]


© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration

LONDON (Reuters) -AstraZeneca said on Friday it was examining the impact of a new coronavirus variant that is spreading rapidly in South Africa on its vaccine and its antibody cocktail, adding it was hopeful its combination drug would retain efficacy.

The World Health Organization (WHO) on Friday designated a new COVID-19 variant B.1.1.529, detected in South Africa with a large number of mutations, as being “of concern”.

AstraZeneca (NASDAQ:) has distributed 2 billion doses of its vaccine worldwide, although rollout of the shot was paused in South Africa in February after it was shown to offer minimal protection against mild to moderate illness caused by the Beta variant, which was dominant in the country at the time.

“As with any new emerging variants, we are looking into B.1.1.529 to understand more about it and the impact on the vaccine,” AstraZeneca said in a statement, adding it was conducting research in Botswana and Eswatini to collect data.

“That will enable us to collect real world data of Vaxzevria against this new virus variant.”

The Anglo-Swedish pharmaceutical firm emphasised that the vaccine has been shown to be effective against all SARS-CoV-2 variants of concern.

AstraZeneca said that it had developed a vaccine platform to respond quickly to new variants with Oxford University, where the vaccine was created. It has previously said it is working on a variant vaccine to better target the Beta variant.

Read More   China calls on e-commerce sites to curb spam ahead of Singles' Day shopping fest

The company has also developed an antibody cocktail which can be used both to prevent and to treat COVID-19.

Although some scientists have expressed concern that the spike protein mutations might hinder the effectiveness of monoclonal antibody drugs, the combination drug made by AstraZeneca might retain its efficacy, the company said.

“We are also testing our long-acting antibody combination AZD7442 against this new variant and are hopeful AZD7442 will retain efficacy since it comprises two potent antibodies with different and complementary activities against the virus,” it said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

[ad_2]

READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.